SCHEMBL299576

SCHEMBL299576

O=C(CCCCCCCCCCCCCCCCCO)OCCO

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.56
GPR84 Q9NQS5 1/20 0.48
FFAR1 O14842 1/20 0.48
FFAR4 Q5NUL3 1/20 0.48
MGLL Q99685 1/20 0.47
DNM1 Q05193 1/20 0.46
GAA P10253 1/20 0.42
PAM P19021 2/20 0.41
KDM4E B2RXH2 2/20 0.40
DUSP3 P51452 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
LMNA P02545 1/20 0.40
EPHX2 P34913 1/20 0.40
PRSS1 P07477 1/20 0.40
PRSS2 P07478 1/20 0.40
PRSS3 P35030 1/20 0.40
TSHR P16473 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL822217 1.00 DGKA (0.56) DGKAGPR84FFAR1FFAR4MGLL
SCHEMBL821826 1.00 DGKA (0.56) DGKAGPR84FFAR1FFAR4MGLL
SCHEMBL275281 1.00 DGKA (0.56) DGKAGPR84FFAR1FFAR4MGLL
SCHEMBL821541 1.00 DGKA (0.56) DGKAGPR84FFAR1FFAR4MGLL
SCHEMBL822209 0.98 DGKA (0.52) DGKAGPR84FFAR1FFAR4MGLL
SCHEMBL19768661 0.96 DGKA (0.52) DGKAGPR84FFAR1FFAR4MGLL
SCHEMBL27601319 0.96 DGKA (0.52) DGKAGPR84FFAR1FFAR4MGLL
SCHEMBL28003204 0.96 DGKA (0.52) DGKAGPR84FFAR1FFAR4MGLL
SCHEMBL15028521 0.96 DGKA (0.52) DGKAGPR84FFAR1FFAR4MGLL
SCHEMBL8065894 0.95 DGKA (0.60) DGKAGPR84FFAR1FFAR4MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 573 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4734923-A1 CLEANSING COMPOSITIONS COMPRISING DIVALENT SALTS L'OREAL (FR) 2026-05-06 EP claimed
US-20250275894-A1 STABLE FOAMED CLEANSING COMPOSITION AND METHODS OF USE L'OREAL (FR) 2025-09-04 US claimed
US-20250009628-A1 CLEANSING COMPOSITIONS COMPRISING DIVALENT SALTS L'OREAL (FR) 2025-01-09 US claimed
EP-4487915-A2 CAPSULE FORMULATIONS ChemoCentryx, Inc. (US) 2025-01-08 EP claimed
WO-2025006412-A1 CLEANSING COMPOSITIONS COMPRISING DIVALENT SALTS L'OREAL (FR) 2025-01-02 WO claimed
US-20240299306-A1 CAPSULE FORMULATIONS CHEMOCENTRYX, INC. 2024-09-12 US claimed
WO-2024131725-A1 TOPICAL PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Shenzhen Pharmacin Co., Ltd. (CN) 2024-06-27 WO claimed
CN-117440858-A Plant-derived vesicles incorporating transmembrane proteins 水通道蛋白有限公司 2024-01-23 CN claimed
US-20230310440-A1 RESPIRATORY STIMULANT NASAL FORMULATIONS ENALARE THERAPEUTICS INC. 2023-10-05 US claimed
WO-2023192602-A2 RESPIRATORY STIMULANT NASAL FORMULATIONS ENALARE THERAPEUTICS INC. (US) 2023-10-05 WO claimed
EP-0705094-B1 SKIN AND SCALP BARRIER FOR USE WITH HAIR TREATMENT PRODUCTS CARSON PROD CO (US) 2000-05-24 EP claimed
EP-0705094-A4 SKIN AND SCALP BARRIER FOR USE WITH HAIR TREATMENT PRODUCTS AMINCO INC (US) 1996-08-07 EP claimed
EP-0705094-A1 SKIN AND SCALP BARRIER FOR USE WITH HAIR TREATMENT PRODUCTS CARSON PRODUCTS COMPANY (US) 1996-04-10 EP claimed
WO-1995000107-A1 SKIN AND SCALP BARRIER FOR USE WITH HAIR TREATMENT PRODUCTS AMINCO, INC. (US) 1995-01-05 WO claimed
EP-0444178-A4 MASCARA COMPOSITION 1992-07-08 EP claimed
EP-0444178-A1 MASCARA COMPOSITION REVLON, INC. (US) 1991-09-04 EP claimed
US-5006170-A Thermal ink jet printing, binders, propellants XEROX CORPORATION (US) 1991-04-09 US claimed
WO-1991004006-A1 MASCARA COMPOSITION REVLON, INC. (US) 1991-04-04 WO claimed
US-4988502-A Cosmetics, pigments treated with lecithin, film forming resin, a humectant REVLON, INC. (US) 1991-01-29 US claimed
US-4173492-A Method of preparing coated pigment particles and the product produced thereby POLLARD EDWARD T 1979-11-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275894-A1 STABLE FOAMED CLEANSING COMPOSITION AND METHODS OF USE DAGLB, MGLL, LIPC DGKA 129/4885GPR84 1787/4885FFAR1 493/4885
US-20250009628-A1 CLEANSING COMPOSITIONS COMPRISING DIVALENT SALTS DAGLB, DSG1, CUTA DGKA 434/4885GPR84 2562/4885FFAR1 1770/4885
US-20230310440-A1 RESPIRATORY STIMULANT NASAL FORMULATIONS ADRA2C, MTNR1B, MTNR1A DGKA 2929/4885GPR84 197/4885FFAR1 362/4885
US-20240299306-A1 CAPSULE FORMULATIONS C5AR1, C1R, C5 DGKA 4826/4885GPR84 786/4885FFAR1 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.